Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables

Atherosclerosis

Volumn 143, Issue 2, 1999, Pages 383-388

  Braeckman, L ^a   De Bacquer, D ^a   Delanghe, J ^a   Claeys, L ^a   De Backer, G ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Apo E; Haptoglobin; Interaction; Lipids; Lipoproteins; Polymorphism

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CORONARY ARTERY DISEASE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC MARKERS; HAPTOGLOBINS; HUMANS; INFLAMMATION; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SENSITIVITY AND SPECIFICITY;

EID: 0032947471     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00330-X     Document Type: Article

References (30)

1. Smithies O., Connell G.E., Dixon G.H. Inheritance of haptoglobin subtypes. Am. J. Hum. Hered. 14:1962;14-21.
2. Langlois M., Delanghe J. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 46:1996;1589-1600.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
4. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New. Engl. J. Med. 320:1989;915-924.
5. Jialal I., Devaraj S. Low-density lipoprotein oxidation, antioxidants and atherosclerosis: a clinical biochemistry perspective. Clin. Chem. 42:1996;498-506.
6. Delanghe J., Cambier B., Langlois M., De Buyzere M., Neels H., De Bacquer D., Van Cauwelaert P. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis. 132:1997;215-219.
7. Delanghe J., Duprez D., De Buyzere M., Bergez B., Callens B., Leroux-Roels G., Clement D. Haptoglobin phenotypes and complications in established essential arterial hypertension. J. Hypertens. 11:1993;861-867.
8. Chapelle J.-P., Albert A., Smeets J.-P., Heusghem C., Kulbertus H.E. Effect of the haptoglobin phenotype on the size of a myocardial infarct. New. Engl. J. Med. 307:1982;457-463.
9. Keys A, editor. Coronary heart disease in seven countries. Circulation 1970;41(Suppl I):1-211.
10. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels the Framingham Study. J. Am. Med. Assoc. 256:1986;2835-2838.
11. Mayo O., Fraser G.R., Stamatoyannopoulos G. Genetic influences on serum cholesterol in two Greek villages. Hum. Hered. 19:1969;86-99.
12. Fraser G.R., Bolkers W.S., Bernini L.F. et al. A search for associations between genetical polymorphic systems and physical, biochemical and haematological variables. Hum. Hered. 24:1974;424-434.
13. Sing C.F., Orr J.D. Analysis of genetic and environmental sources of variation in serum cholesterol in Tecumsen, Michigan; III Identification of genetic effects using 12 polymorphic blood marker systems. Am. J. Hum. Genet. 28:1976;453-464.
14. Buckton K., Lai L., Gibson J. A search for association between gene markers and serum cholesterol, triglycerides, urate and blood pressure. Ann. Hum. Biol. 8:1981;39-48.
15. Fröhlander N. Haptoglobin groups and serum cholesterol levels. Hum. Hered. 37:1987;323-325.
16. Borresen A.-L., Leren T., Berg K., Solaas M.H. Effect of haptoglobin subtypes on serum lipid levels. Hum. Hered. 37:1987;150-156.
17. Sing C.F., Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37:1985;268-285.
18. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis. 8:1988;1-21.
19. Hallman D.M., Boerwinkle E., Saha N., Sandholzer C., Menzel H.J., Csazar A., Utermann G. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am. J. Hum. Genet. 49:1991;338-349.
20. Braeckman L., De Bacquer D., Rosseneu M., De Backer G. Apolipoprotein E polymorphism in middle-aged Belgian men. Phenotype distribution and relation to serum lipids and lipoproteins. Atherosclerosis. 120:1996;67-73.
21. Smithies O. Zone electrophoresis in starch gels: grouped variations in the serum proteins of normal human adults. Biochem. J. 61:1955;629-641.
22. Havekes L., de Knijff P., Reisiegel U., Havinga J., Smit M., Klasen E. A rapid micro-method for apolipoprotein E phenotyping directly in serum. J. Lipid. Res. 28:1987;445-463.
23. Rosseneu M., Vinaimont N., Vercaemst R., De Keersgieter W., Belpaire F. Standardization of immunoassays for the quantification of plasma apo B protein. Anal. Biochem. 116:1981;204-210.
24. Bury J., Vercaemst R., Rosseneu M., Belpaire F. Apolipoprotein E quantified by enzyme-linked immunosorbent assay. Clin. Chem. 32:1986;265-270.
25. Labeur C., Michiels G., Bury J., Usher D.C., Rosseneu M. Lipoprotein LP(a) quantified by an enzyme-linked immunosorbent assay with monoclonal antibodies. Clin. Chem. 35:1989;1380-1385.
26. Vercaemst R., Union A., Rosseneu M., De Craene I., De Backer G., Kornitzer M. Quantitation of plasma free cholesterol and cholesteryl esters by high-performance liquid chromatography: study of a normal population. Atherosclerosis. 78:1989;245-250.
27. De Boever E., De Bacquer D., Braeckman L., Baele G., Rosseneu M., De Backer G. Relation of fibrinogen to lifestyles and to cardiovascular risk-factors in a working population. Int. J. Epidemiol. 24(5):1995;915-921.
28. SAS/STAT User's Guide, Release 6-04 edition. Cary, NC: SAS Institute Inc., 1988.
29. Cobbaert C., Mulder P. Regional serum cholesterol differences in Belgium: do genetically determined cardiovascular risk factors contribute? Int. J. Epidemiol. 27:1998;605-613.
30. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. New. Engl. J. Med. 336:1997;973-979.